Diabetes management leader Dexcom breaks into EMEA markets with new Edinburgh HQ
Office opens on World Diabetes Day - quarter million Scots suffer from diabetes
EDINBURGH, Scotland, Nov. 14, 2016 - Dexcom (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM) for patients with diabetes, today announced the opening of its EMEA HQ in Edinburgh, Scotland, creating over 60 new jobs for the region within the next three years.
The office was officially inaugurated by Keith Brown MSP, Cabinet Secretary for the Economy, Jobs and Fair Work, on World Diabetes Day and will support various Dexcom business functions for Europe, the Middle-East and Africa.
This is a significant milestone as it provides patients across the EMEA regions with access to Dexcom’s world-class technology, which includes a CGM sensor that sits just below the skin's surface and is attached to a transmitter which wirelessly transfers real-time glucose levels every five minutes to mobile applications via Bluetooth.
The new premises, based in Tanfield, enjoy the support of Scottish Enterprise and serve as the launch pad to distribute Dexcom’s suite of Mobile CGM Systems into EMEA markets. Our latest offering, the Dexcom G5 Mobile CGM System is the world’s first mobile CGM system that is compatible with iOS operating systems.
"With its strong history of medical innovation, the incredible talent pool in the city and the strategic inward investment through Scottish Enterprise, Edinburgh really stood out to us as a location," explained John Lister, General Manager, EMEA, of Dexcom. "We are excited to bring the benefits of our state-of-the-art glucose monitoring solutions to diabetes patients across Europe, Africa and the Middle East, and build our brand and future commercial business from Scotland."
Cabinet Secretary for the Economy, Jobs and Fair Work, Keith Brown, said: “On a day like World Diabetes Day, a day that reminds us of the challenges faced by people living with diabetes, I am particularly pleased that an international company like Dexcom recognises the strength of Scotland’s life science sector and chose Edinburgh as their new European headquarters. I look forward to hearing of technological advances developed here that will enhance the lives of people living with diabetes and I wish them all the best for the future.”
Managing Director of Scottish Development International, Paul Lewis, said: “With exceptional strengths in both life sciences and digital technologies, Scotland is the ideal location for Dexcom’s European headquarters. The company will now join the many international investors who benefit from our competitive business environment, strong skills base and effective support network, which help make Scotland the top performing location for inward investment after London. We look forward to supporting Dexcom’s ambitious growth plans for Europe, the Middle-East and Africa.”
A quarter of a million people are affected by diabetes in Scotland, with 13% living with type 1 diabetes and 87% living with type 2 diabetes.
Dexcom operates internationally and is headquartered in San Diego, California.
+++ END +++
Boiler Plate
About Dexcom, Inc.
Founded in 1999, Dexcom, Inc. is transforming diabetes care and management by providing superior continuous glucose monitoring (CGM) technology to help patients and healthcare professionals better manage diabetes. Since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions that are best in class—while empowering our community to take control of diabetes. For more information on Dexcom CGM, visit www.dexcom.com
Scottish Enterprise is Scotland's main economic development agency and aims to deliver a significant, lasting effect on the Scottish economy by identifying and exploiting the best opportunities for economic growth.
Scottish Development International (SDI) is a partnership between the Scottish Government, Scottish Enterprise and Highlands and Islands Enterprise, which works to attract inward investment to Scotland and helps Scottish based companies to trade overseas.
Further Information
Diabetes: A World-Wide Emergency
Diabetes is one of the largest global health emergencies of the 21st century. Each year more and more people live with this condition, which can result in life-changing complications. In addition to the
415 million adults who are estimated to currently have diabetes, there are 318 million adults with impaired glucose tolerance, which puts them at high risk of developing the disease in the future. According to the International Diabetes Foundation (IDF), there are 52 million people living with diabetes in Europe and by 2040, it is estimated that more than 72 million people will have the disease.3 With diabetes, the body cannot produce or use the hormone insulin effectively, causing a buildup of glucose, or sugar, in the blood. There are also around 17 million people in Europe who have diabetes but have not been diagnosed. They may be experiencing symptoms they can’t explain, or they may assume that the symptoms are due to other causes, such as getting older or having a busy lifestyle.4 People with diabetes who take insulin must monitor their blood glucose levels frequently. Uncontrolled glucose can cause health complications and even death.4,5
Enhanced Mobility and Flexibility
Dexcom G5 Mobile CGM System is the world’s only CGM system that provides consistent, accurate1 sensing performance with MARD (Mean Absolute Relative Difference) of 10% or less for both adults and children as young as 2 years old. G5 Mobile offers the longest-wear sensor on the market and provides patients with the freedom to make treatment decisions without the need for confirmatory fingersticks.2 G5 Mobile features real-time customizable alerts and a built-in low glucose alarm (3.1 mmol/L 55 mg/dL alarm) to help patients respond quickly to or avoid potentially dangerous hypoglycemic events. Patients can also customize alerts notifying them of impending lows and highs. In addition, G5 Mobile offers patients the ability to stay connected in real-time with loved ones by sharing their CGM data with up to 5 followers via the Follow App.
References
- Dexcom G5 Mobile Continuous Glucose Monitoring System, User’s Guide, 2015.
- If your glucose alerts and readings do not match your symptoms or expectations, you should obtain a fingerstick. A minimum of two fingersticks a day is required for calibration.
- IDF Diabetes Atlas
- Hyperglycemia (High blood glucose). American Diabetes Association Web site. http://www.diabetes.org/living-with-diabetes/treatment-and-care/blood-glucose-control/hyperglycemia.html. Updated August 5, 2013. Accessed December 3, 2013.
- Hypoglycemia (Low blood glucose). American Diabetes Association Web site. http://www.diabetes.org/living-with-diabetes/treatment-and-care/blood-glucose-control/hypoglycemia-low-blood.html. Updated July 16, 2013. Accessed December 3, 2013.
DEXCOM CONTACT:
John Bernard
To view multimedia assets, please visit: http://dexcom.media
INVESTOR CONTACT:
Steven Pacelli, 858-200-0200